JAZZ vs NDRA · P/E 1988, rev $4.07B vs P/E 0.0, $2.6M cap
Jazz Pharmaceuticals PLC (JAZZ) versus ENDRA Life Sciences Inc (NDRA) — a side-by-side from cached financials, not a winner call.
Jazz Pharmaceuticals PLC (JAZZ) is a biotechnology company listed on US.
ENDRA Life Sciences Inc (NDRA) is a diagnostics & research company listed on US.
Latest reported JAZZ revenue for 2024-12-31 was $4.07B. Net income was $560.1M. Revenue was up 6.1% from 2023-12-31 to 2024-12-31. JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1.
NDRA does not have a complete income-statement cache yet.
JAZZ currently screens at market cap $14.97B and trailing P/E 1988.1. NDRA currently screens at market cap $2.6M and trailing P/E 0.0.
Not investment advice. Open the JAZZ and NDRA stock pages for the full models.
Not investment advice.